Endoscopic treatment as secondary prophylaxis ameliorates short-term mortality for acute esophagogastric variceal bleeding in older patients with cirrhotic hepatocellular carcinoma.
{"title":"Endoscopic treatment as secondary prophylaxis ameliorates short-term mortality for acute esophagogastric variceal bleeding in older patients with cirrhotic hepatocellular carcinoma.","authors":"Qi Li, Ruifeng Liu, Shenghui Zhou, Lingna Lyu, Chunlei Fan, Huiguo Ding","doi":"10.1177/20406223251356824","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Acute esophagogastric variceal bleeding (AEGVB) is a common complication of liver cirrhosis and hepatocellular carcinoma (HCC). It is unclear if older patients with cirrhotic HCC benefit from endoscopic treatment as secondary prophylaxis for AEGVB in short term.</p><p><strong>Objectives: </strong>We aim to investigate if endoscopic treatment as secondary prophylaxis for AEGVB reduces short-term mortality in older patients with cirrhotic HCC.</p><p><strong>Design: </strong>We retrospectively enrolled 138 consecutive patients over 60 years old with cirrhotic HCC and AEGVB from April 1, 2021 through December 31, 2022 in Emergency Room, Beijing You'an Hospital, Capital Medical University.</p><p><strong>Methods: </strong>A 1:1 propensity score matching (PSM) analysis was performed to adjust for confounding factors such as age, gender, Child-Pugh score in our statistical findings. Logistic regression and Cox regression analyses were used to investigate whether there was a significant negative association between endoscopic treatment and short-term mortality for AEGVB in older patients with cirrhotic HCC. Kaplan-Meier methodology was employed to compare overall survival over 6 weeks between the endoscopic treatment group and non-endoscopic treatment group.</p><p><strong>Results: </strong>In older patients with cirrhotic HCC and AEGVB, in-hospital mortality and 6-week mortality were significantly lower in the endoscopic treatment group compared to the non-endoscopic treatment group before PSM (5.33% vs 26.98%, <i>p</i> = 0.001 for in-hospital mortality; 12.00% vs 44.44%; <i>p</i> < 0.001 for 6-week mortality). These results remained consistent after PSM (4.76% vs 26.98%, <i>p</i> = 0.002 for in-hospital mortality; 9.52% vs 44.44%; <i>p</i> < 0.001 for 6-week mortality). Both logistic regression and Cox regression analyses found that endoscopic treatment contributed to reduced short-term mortality for AEGVB in older patients with cirrhotic HCC. Kaplan-Meier survival curves indicated that older patients undergoing endoscopic treatment had a higher short-term survival rate than those who didn't receive endoscopic treatment in our cohort. However, there was no significant difference in short-term survival between patients receiving endoscopic variceal ligation and those treated with endoscopic injection sclerotherapy.</p><p><strong>Conclusion: </strong>Secondary prophylaxis of endoscopic treatment helps to reduce 6-week mortality for AEGVB in older patients with cirrhotic HCC. Therefore, endoscopic treatment is suggested to be employed as secondary prophylaxis in this special population in clinical practice.</p>","PeriodicalId":22960,"journal":{"name":"Therapeutic Advances in Chronic Disease","volume":"16 ","pages":"20406223251356824"},"PeriodicalIF":2.8000,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12317264/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Chronic Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/20406223251356824","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Acute esophagogastric variceal bleeding (AEGVB) is a common complication of liver cirrhosis and hepatocellular carcinoma (HCC). It is unclear if older patients with cirrhotic HCC benefit from endoscopic treatment as secondary prophylaxis for AEGVB in short term.
Objectives: We aim to investigate if endoscopic treatment as secondary prophylaxis for AEGVB reduces short-term mortality in older patients with cirrhotic HCC.
Design: We retrospectively enrolled 138 consecutive patients over 60 years old with cirrhotic HCC and AEGVB from April 1, 2021 through December 31, 2022 in Emergency Room, Beijing You'an Hospital, Capital Medical University.
Methods: A 1:1 propensity score matching (PSM) analysis was performed to adjust for confounding factors such as age, gender, Child-Pugh score in our statistical findings. Logistic regression and Cox regression analyses were used to investigate whether there was a significant negative association between endoscopic treatment and short-term mortality for AEGVB in older patients with cirrhotic HCC. Kaplan-Meier methodology was employed to compare overall survival over 6 weeks between the endoscopic treatment group and non-endoscopic treatment group.
Results: In older patients with cirrhotic HCC and AEGVB, in-hospital mortality and 6-week mortality were significantly lower in the endoscopic treatment group compared to the non-endoscopic treatment group before PSM (5.33% vs 26.98%, p = 0.001 for in-hospital mortality; 12.00% vs 44.44%; p < 0.001 for 6-week mortality). These results remained consistent after PSM (4.76% vs 26.98%, p = 0.002 for in-hospital mortality; 9.52% vs 44.44%; p < 0.001 for 6-week mortality). Both logistic regression and Cox regression analyses found that endoscopic treatment contributed to reduced short-term mortality for AEGVB in older patients with cirrhotic HCC. Kaplan-Meier survival curves indicated that older patients undergoing endoscopic treatment had a higher short-term survival rate than those who didn't receive endoscopic treatment in our cohort. However, there was no significant difference in short-term survival between patients receiving endoscopic variceal ligation and those treated with endoscopic injection sclerotherapy.
Conclusion: Secondary prophylaxis of endoscopic treatment helps to reduce 6-week mortality for AEGVB in older patients with cirrhotic HCC. Therefore, endoscopic treatment is suggested to be employed as secondary prophylaxis in this special population in clinical practice.
背景:急性食管胃静脉曲张出血(AEGVB)是肝硬化和肝癌(HCC)的常见并发症。目前尚不清楚老年肝硬化HCC患者是否能从内镜治疗作为AEGVB的二级预防在短期内获益。目的:我们的目的是研究内镜治疗作为AEGVB的二级预防是否能降低老年肝硬化HCC患者的短期死亡率。设计:从2021年4月1日至2022年12月31日,我们在首都医科大学北京佑安医院急诊室回顾性招募了138例60岁以上的肝硬化HCC和AEGVB患者。方法:采用1:1倾向评分匹配(PSM)分析,对统计结果中的年龄、性别、Child-Pugh评分等混杂因素进行校正。采用Logistic回归和Cox回归分析探讨内镜治疗与老年肝硬化HCC患者AEGVB短期死亡率之间是否存在显著负相关。采用Kaplan-Meier方法比较内镜治疗组和非内镜治疗组6周以上的总生存率。结果:在老年肝硬化HCC和AEGVB患者中,内镜治疗组住院死亡率和6周死亡率显著低于PSM前非内镜治疗组(5.33% vs 26.98%, p = 0.001);12.00% vs 44.44%;住院死亡率P = 0.002;9.52% vs 44.44%;结论:内镜治疗的二级预防有助于降低老年肝硬化HCC患者AEGVB的6周死亡率。因此,在临床实践中,内镜治疗建议作为这一特殊人群的二级预防措施。
期刊介绍:
Therapeutic Advances in Chronic Disease publishes the highest quality peer-reviewed research, reviews and scholarly comment in the drug treatment of all chronic diseases. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers involved in the medical treatment of chronic disease, providing a forum in print and online for publishing the highest quality articles in this area.